Levitra

Levitra is a brand name of vardenafil, approved by the FDA in the following formulation(s):

LEVITRA (vardenafil hydrochloride - tablet; oral)

• 
  Manufacturer: BAYER HLTHCARE
  
  Approval date: August 19, 2003
  
  Strength(s): 10MG, 2.5MG, 20MG ^[RLD], 5MG
  

Has a generic version of Levitra been approved?

No. There is currently no therapeutically equivalent version of Levitra available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Levitra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
  Patent 6,362,178
  Issued: March 26, 2002
  Inventor(s): Ulrich; Niewöhner & Mazen; Es-Sayed & Helmut; Haning & Thomas; Schenke & Karl-Heinz; Schlemmer & Jörg; Keldenich & Erwin; Bischoff & Elisabeth; Perzborn & Klaus; Dembowsky & Peter; Serno & Marc; Nowakowski
  Assignee(s): Bayer Aktiengesellschaft
  The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
  
  Patent expiration dates:
  
  
  • October 31, 2018
    
    ✓ 
    Patent use: ERECTILE DYSFUNCTION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
  Patent 7,696,206
  Issued: April 13, 2010
  Inventor(s): Niewöhner; Ulrich & Es-Sayed; Mazen & Haning; Helmut & Schenke; Thomas & Schlemmer; Karl-Heinz & Keldenich; Jorg & Bischoff; Erwin & Perzborn; Elisabeth & Dembowsky; Klaus & Serno; Peter & Nowakowski; Marc
  Assignee(s): Bayer Schering Pharma Aktiengesellschaft
  The application claims a compound of the formula or a salt, a hydrate, or a hydrate of a salt thereof. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of erectile dysfunction.
  
  Patent expiration dates:
  
  
  • October 31, 2018
    
    ✓ 
    Patent use: ERECTILE DYSFUNCTION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Levitra Consumer Information (Drugs.com)
• Levitra Consumer Information (Wolters Kluwer)
• Levitra Consumer Information (Cerner Multum)
• Levitra Advanced Consumer Information (Micromedex)
• Levitra AHFS DI Monographs (ASHP)
• Vardenafil Consumer Information (Wolters Kluwer)
• Vardenafil Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
• Vardenafil Consumer Information (Cerner Multum)
• Vardenafil Advanced Consumer Information (Micromedex)
• Vardenafil Hydrochloride AHFS DI Monographs (ASHP)